---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-262193"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2022-10-13T23:59:59+00:00"
generated_at: "2026-06-23T03:53:20.205454+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data

## Summary
- Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.
- Will hold investor webcast on December 14, 2022 to present clinical data from KT-474 and oncology pipeline.
- KT-333 (STAT3 degrader) and KT-413 (IRAKIMiD) continuing Phase 1 dose escalation.
- KT-253 (MDM2 degrader) has completed IND enabling studies; expects to file IND by year-end 2022.
- Collaboration with Sanofi for IRAK4 degrader development outside oncology/immune-oncology.

## SEC filing metadata
- accession: 0001193125-22-262193
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2022-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/0001193125-22-262193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/d396584d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-262193
- JSON: https://secwatch.observer/filing/0001193125-22-262193.json
- Plain text: https://secwatch.observer/filing/0001193125-22-262193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.